Diversity & Equality

STATEMENT ON OUR COMMITMENT TO DIVERSITY AND EQUALITY

At Neurocrine Biosciences, our values are incompatible with racism, hatred, and injustice. We believe in tolerance, equality, and embracing our differences, and we condemn bigotry and violence in all forms.

The killings of George Floyd, Breonna Taylor, and Ahmaud Arbery, and now Rayshard Brooks, are a sobering reminder of the long road ahead in the fight against racial inequality and injustice.

We know that words alone are not enough. There are no simple solutions to these complex and deeply rooted problems. Listening to each other, thoughtful deliberation, and impactful actions over time are required to create a more just society for all.

We are engaging in conversations with our colleagues at every level, including our Board of Directors, to identify specific actions to drive positive change in our company and our community.  But we acknowledge these discussions must only be initial next steps in our commitment to promoting diversity, inclusion, tolerance, and equality.

We invite both internal and external feedback. We will hold ourselves accountable, and we encourage our colleagues, shareholders, patients, partners and members of our communities to hold us accountable as well.

Neurocrine Biosciences Management Committee
Kevin C. Gorman, Ph.D. – Chief Executive Officer

Matthew C. Abernethy – Chief Financial Officer
Eric Benevich – Chief Commercial Officer
David W. Boyer – Chief Corporate Affairs Officer
Haig P. Bozigian, Ph.D. – Chief Development Officer
Julie Cooke – Chief Human Resources Officer
Kyle Gano, Ph.D. – Chief Business Development and Strategy Officer
Dimitri E. Grigoriadis, Ph.D. – Chief Research Officer
Darin M. Lippoldt – Chief Legal Officer
Malcolm Lloyd-Smith – Chief Regulatory Officer
Eiry W. Roberts, M.D. – Chief Medical Officer